Khosrotehrani Group - Grants - Frazer Institute

Our work is funded essentially from the NHMRC, ARC and some industry partners.

2017-2020. NHMRC CDF2. Modulating skin regenerative responses to improve wound repair and fight carcinogenesis. $470,144. Khosrotehrani.
2020-2021: PR190852 US Department of Defense: Molecular Targets in Endovascular Progenitors to Inhibit Lung and Skin Fibrosis in Scleroderma. AU$278000 (Exact amount in negotiation). Khosrotehrani, Thomas, Talekar.
2019-2021: APP1163986 NHMRC Project grant: Targeting the pre-metastatic vascular niche in melanoma using a novel molecular strategy. AU$843,856.80. Khosrotehrani, Francois, Barbour, Patel.
2019-2021: DP190103187 ARC Discovery. Potency and activity of Meso-Endothelial bipotent progenitors in vivo. $350,000 Khosrotehrani, Patel, Yoder.
2018-2021: APP1145350 NHMRC Project grant. Fighting epidermal skin cancers by targeting epidermal clones that accumulate mutations. $1,149,373.20. Khosrotehrani, Soyer, Saunders, Fink, Roy.

Grants

Fellowship:

2021-2023: Queensland Advancing Clinical Research Fellowship: Reducing the burden of skin cancers through advanced chemo-immuno-prophylaxis. AU$500,000. Khosrotehrani
2017-2020. Modulating skin regenerative responses to improve wound repair and fight carcinogenesis. NHMRC CDF2. $470,144. Khosrotehrani
2016-2018: UQ Fellowship- Service Stream
2012-2015, APP1023371 NHMRC Career Development Fellowship Award level 1: Regenerative medicine in dermatology. AU$102,800 per year.

As Principal Investigator:

2021-2024: Cancer Council Queensland: Accelerating Collaborative Cancer Research (ACCR) Grants. Advanced technological approach to predicting survival in patients diagnosed with locally invasive cutaneous melanoma. AU$2,000,000. Khosrotehrani, Hayward, Stark, Whiteman, Barbour, Smithers, Soyer, Green, Nguyen, MacGregor, Olsen, Pandeya, Lambie
2021-2025: Q Health-Herston Biofabrication Institute Dermatology program: AU$1,000,000. Khosrotehrani, Rowan
2020-2021: Eli Lilly PTY LTD. Investigator initiated trial. IXEHEAL: Phase II study of ixekizumab for chronic venous ulcers. $124,649. Khosrotehrani
2019-2020: Genesis care: Volumetric Modulated Arc Therapy (VMAT) Irradiation in Skin Cancer Incidence Prevention: A randomised, open-label, single arm, phase II, controlled trial. A feasibility evaluation. $126,000. Khosrotehrani
2020-2022: DOD Discovery PR190852: Molecular Targets in Endovascular Progenitors to Inhibit Lung and Skin Fibrosis in Scleroderma. US$221,000. Khosrotehrani, Thomas, Talekar